ReviewJournal of leukocyte biology2012
Biochemical and cellular implications of a dual lipase-GEF function of phospholipase D2 (PLD2).
Review in Journal of leukocyte biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Phospholipase D2 is a positive regulator of sirtuin 1 and modulates p53-mediated apoptosis via sirtuin 1.Experimental & molecular medicine · 2021Article
- Identification and functional analysis of a novel phospholipase D2 gene mutation associated with familial systemic lupus erythematosus.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2021Article
- Pleckstrin homology domain of phospholipase D2 is a negative regulator of focal adhesion kinase.BMB reports · 2021Article
- Phospholipase D and phosphatidic acid in the biogenesis and cargo loading of extracellular vesicles.Journal of lipid research · 2018Review
- A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells.Blood cancer journal · 2016Article
- Phospholipase D2 promotes degradation of hypoxia-inducible factor-1α independent of lipase activity.Experimental & molecular medicine · 2015Article
- Phospholipase D1 protein coordinates dynamic assembly of HIF-1α-PHD-VHL to regulate HIF-1α stability.Oncotarget · 2014Article
- Phospholipase D (PLD) drives cell invasion, tumor growth and metastasis in a human breast cancer xenograph model.Oncogene · 2013Article
- The Concise Guide to PHARMACOLOGY 2013/14: enzymes.British journal of pharmacology · 2013Article
- Macrophage migration arrest due to a winning balance of Rac2/Sp1 repression over β-catenin-induced PLD expression.Journal of leukocyte biology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
PLD2 plays a key role in cell membrane lipid reorganization and as a key cell signaling protein in leukocyte chemotaxis and phagocytosis. Adding to the large role for a lipase in cellular functions, recently, our lab has identified a PLD2-Rac2 binding through two CRIB domains in PLD2 and has defined PLD2 as having a new function, that of a GEF for Rac2. PLD2 joins other major GEFs, such as P-Rex1 and Vav, which operate mainly in leukocytes. We explain the biochemical and cellular implications of a lipase-GEF duality. Under normal conditions, GEFs are not constitutively active; instead, their activation is highly regulated. Activation of PLD2 leads to its localization at the plasma membrane, where it can access its substrate GTPases. We propose that PLD2 can act as a "scaffold" protein to increase efficiency of signaling and compartmentalization at a phagocytic cup or the leading edge of a leukocyte lamellipodium. This new concept will help our understanding of leukocyte crucial functions, such as cell migration and adhesion, and how their deregulation impacts chronic inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.